Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, limited research is documented on platinum-based treatment prediction with HRD as a biomarker in ovarian cancer patients, especially in the Chinese population. This first-ever China prospective cohort study, jointly conducted by BGI Genomics clinical researcher Dr. Shao Di and the Fudan University Shanghai Cancer Center team and published on the Journal of Ovarian Research indicates that HRD testing can accurately predict the sensitivity of platinum-based chemotherapy for ovarian cancer patients. Research Method The study covered 240 patients with primary treatment of high-grade serious ovarian cancer (HGSOC) admitted to the Cancer Hospital of Fudan University from January 2016 to September 2018 interval. Patients received more than two cycles of platinum-containing adjuvant chemotherapy after surgery and were classified as platinum-sensitive (Pt) and platinum-resistant according to the time of ovarian cancer recurrence. All patients were tested with a gene panel test screening for 68 HRR genes, to assess the mutation status of HRR-related genes such as BRCA. Of these, 118 samples underwent the HRD test to assess loss of heterozygosity (LOH), telomere allele disequilibrium (TAI), and large segmental recombination abnormality (LST) status. The Kaplan-Meier method was used to plot survival curve and the effectiveness of these tests in predicting patient outcomes. Conclusion This study demonstrated for the first time that HRD is a valid biomarker tool for predicting sensitivity to platinum-based chemotherapy in prospective cohort unselected Chinese ovarian cancer patients. The study also found a higher rate of HRD positivity in Chinese ovarian cancer patients than in Western populations, suggesting that HRD testing could screen a higher proportion of Chinese PARP inhibitor population to facilitate precision therapy. About BGI Genomics BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover over 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. Additional Readings: https://www.twine.net/signin https://www.twine.net/signin https://www.twine.net/signin bgichina bgigenetest
- Actor